FCA
DFTX

FinTrust Capital Advisors’s Definium Therapeutics DFTX Stock Holding History

FinTrust Capital Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-33
Closed -$104 – 1311
2023
Q3 		$104 Hold
33
– – ﹤0.01% 1207
2023
Q2 		$73 Hold
33
– – ﹤0.01% 1187
2023
Q1 		$73 Hold
33
– – ﹤0.01% 1176
2022
Q4 		$73 Hold
33
– – ﹤0.01% 1174
2022
Q3 		$0 Buy
+33
New +$317 ﹤0.01% 1251

Other funds holding DFTX

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

FinTrust Capital Advisors's DFTX Position: Q4 2023 in Review

FinTrust Capital Advisors sold out of Definium Therapeutics (DFTX) in Q4 2023, closing a stake of 33 shares — an estimated $104 sold.

FinTrust Capital Advisors first reported a position in DFTX in Q3 2022 and held it in 5 quarters. The position peaked at $104 in Q3 2023. 104 funds tracked by Wall St. Rank hold DFTX as of Q4 2023.

  • FinTrust Capital Advisors reported no remaining Definium Therapeutics position as of Q4 2023 after selling out during the quarter.
  • FinTrust Capital Advisors sold 33 Definium Therapeutics shares in Q4 2023, an estimated $104.
  • FinTrust Capital Advisors first reported a position in Definium Therapeutics in Q3 2022 and held it in 5 quarters.
  • FinTrust Capital Advisors's Definium Therapeutics position peaked at $104 in Q3 2023.
  • 104 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2023.

Based on FinTrust Capital Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.